UK US CA
Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.
Research → decisions → accessEvidence checked 13 Sep 2026

Follow the science.
See what comes next.

A clearer view of the milestones shaping peptide and GLP-1 medicines in the UK, US and EU: confirmed decisions, company targets and clearly labelled estimates, each with its source. What we track · How estimates are made.

Eloralintide

Eli Lilly · Amylin receptor agonist · Peptide · Investigational
RangeNext four yearsAll milestonesZoomQuartersYears
Region
Q2 2026Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028
USFDA
TodayNo verified events yet
UKMHRA
No verified events yet
EUEMA / European Commission
No verified events yet

No verified events recorded yet.

Confirmed eventCompany targetRegulator targetEditorial estimateTiming unknown or undatedSafety update

Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.

No verified records yet for Eloralintide. See coverage.

Select a milestone to see its evidence. Keyboard: Tab to a marker, arrow keys to move, Enter to open.Estimates describe timing only, never a probability of approval.

All Eloralintide records (accessible list)

Eloralintide

Investigational amylin receptor agonist in Phase 3 for obesity.

United Kingdom

No verified events recorded yet. Regulator: MHRA.

United States

No verified events recorded yet. Regulator: FDA.

European Union

No verified events recorded yet. Regulator: EMA / European Commission.

This list is the complete, accessible view of the tracker; the board above draws from exactly the same records. Every entry is labelled Confirmed (official record), Company target (a dated sponsor statement), Regulator target (an official decision date, not a guarantee), GLPInfo estimate (an editorial range with assumptions) or Timing unknown. An approval is never inferred from a target date passing.